Azitra (AZTR) Other Accumulated Expenses (2022 - 2023)
Azitra (AZTR) posted Other Accumulated Expenses of $23647.0 for Q4 2023, up 649.51% on a QoQ basis from $3155.0 in Q3 2023, and down 24.17% year-over-year from $31186.0 in Q4 2022.
Azitra (AZTR) Other Accumulated Expenses (2022 - 2023) Analysis & Trends
Azitra's Other Accumulated Expenses history runs 2 years deep, the most recent figure standing at $23647.0 for Q4 2023.
- Quarterly Other Accumulated Expenses fell 24.17% year-over-year to $23647.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $23647.0 (down 24.17% YoY) and the FY2023 annual result came in at $23647.0, down 24.17% from the prior year.
- Other Accumulated Expenses was $23647.0 for Q4 2023 at Azitra, up from $3155.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $31186.0 in Q4 2022 and bottomed at $3155.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Nanobiotix | 1,792.52 Bn | 1,792.46 Bn | - |
| 2 | Akari Therapeutics | 999.95 Bn | 999.95 Bn | - |
| 3 | BeOne Medicines | 475.97 Bn | 471.17 Bn | 1.35 Bn |
| 4 | Vertex Pharmaceuticals | 124.91 Bn | 117.66 Bn | 2.59 Bn |
| 5 | Regeneron Pharmaceuticals | 72.31 Bn | 63.56 Bn | 3.31 Bn |
| 6 | Belite Bio | 62.01 Bn | 62.01 Bn | - |
| 7 | Argenx Se | 54.23 Bn | 49.04 Bn | 1.41 Bn |
| 8 | Alnylam Pharmaceuticals | 38.31 Bn | 35.30 Bn | 959.66 Mn |
| 9 | Revolution Medicines | 36.16 Bn | 36.16 Bn | - |
| 10 | Azitra | 2.05 Mn | 2.05 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 23,647.00 |
| Sep 30, 2023 | 3,155.00 |
| Jun 30, 2023 | 4,258.00 |
| Dec 31, 2022 | 31,186.00 |